MedTrace Logo

Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis

NCT03810521 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-01-18

No results posted yet for this study

Summary

A phase I dose-escalation trial to assess safety and efficacy of allogeneic MSC based-treatment (cellistem-OA) in patients with symptomatic knee osteoarthritis

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

umbilical cord derived-mesenchymal stromal cells

Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells

Sponsors & Collaborators

  • Universidad de los Andes, Chile

    lead OTHER

Principal Investigators

  • Francisco Espinoza, MD · CMO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2019-10-30
Completion
2019-12-30

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03810521 on ClinicalTrials.gov